| mRNA |
crizotinib:PLX-4032 (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.068 |
0.06 |
| mRNA |
MS-275 |
CTRPv2 |
pan-cancer |
AAC |
0.064 |
0.06 |
| mRNA |
selumetinib:PLX-4032 (8:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.07 |
0.06 |
| mRNA |
BRD-K16147474 |
CTRPv2 |
pan-cancer |
AAC |
0.077 |
0.06 |
| mRNA |
BRD-K51490254 |
CTRPv2 |
pan-cancer |
AAC |
0.072 |
0.07 |
| mRNA |
lapatinib |
gCSI |
pan-cancer |
AAC |
0.1 |
0.07 |
| mRNA |
OSI-906 |
CTRPv2 |
pan-cancer |
AAC |
0.067 |
0.07 |
| mRNA |
sirolimus:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.065 |
0.07 |
| mRNA |
CIL70 |
CTRPv2 |
pan-cancer |
AAC |
-0.082 |
0.08 |
| mRNA |
SR-II-138A |
CTRPv2 |
pan-cancer |
AAC |
0.059 |
0.08 |